Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromatin | 2 | 2021 | 76 | 1.450 |
Why?
|
| Pluripotent Stem Cells | 4 | 2019 | 42 | 1.330 |
Why?
|
| Induced Pluripotent Stem Cells | 3 | 2021 | 86 | 1.320 |
Why?
|
| Hepatocytes | 4 | 2017 | 205 | 1.190 |
Why?
|
| GATA6 Transcription Factor | 1 | 2021 | 27 | 0.760 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 8 | 0.730 |
Why?
|
| Liver | 3 | 2022 | 1118 | 0.600 |
Why?
|
| Models, Biological | 2 | 2019 | 981 | 0.570 |
Why?
|
| Liver Diseases | 1 | 2019 | 193 | 0.570 |
Why?
|
| Toxicology | 1 | 2016 | 14 | 0.540 |
Why?
|
| Pharmacology | 1 | 2016 | 9 | 0.540 |
Why?
|
| Proteome | 1 | 2016 | 87 | 0.510 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2015 | 35 | 0.490 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 58 | 0.490 |
Why?
|
| Cell Differentiation | 5 | 2021 | 1034 | 0.480 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2016 | 328 | 0.470 |
Why?
|
| Stem Cells | 1 | 2015 | 248 | 0.440 |
Why?
|
| Fibroblasts | 1 | 2017 | 902 | 0.410 |
Why?
|
| Chemical and Drug Induced Liver Injury | 3 | 2014 | 131 | 0.230 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2022 | 4 | 0.220 |
Why?
|
| Receptors, Virus | 1 | 2022 | 20 | 0.210 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2673 | 0.190 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2020 | 9 | 0.190 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2020 | 25 | 0.180 |
Why?
|
| Organogenesis | 1 | 2020 | 49 | 0.180 |
Why?
|
| Neovascularization, Physiologic | 1 | 2020 | 164 | 0.170 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 371 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 331 | 0.160 |
Why?
|
| Clinical Protocols | 1 | 2019 | 172 | 0.150 |
Why?
|
| Embryonic Stem Cells | 2 | 2014 | 40 | 0.150 |
Why?
|
| Humans | 10 | 2022 | 68618 | 0.150 |
Why?
|
| Cell Dedifferentiation | 1 | 2016 | 4 | 0.140 |
Why?
|
| Uncoupling Agents | 1 | 2016 | 10 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2020 | 753 | 0.140 |
Why?
|
| Rotenone | 1 | 2016 | 10 | 0.140 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 20 | 0.140 |
Why?
|
| Animals | 4 | 2022 | 20881 | 0.130 |
Why?
|
| Protein Stability | 1 | 2016 | 90 | 0.130 |
Why?
|
| Mitochondria | 1 | 2020 | 643 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 163 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2077 | 0.130 |
Why?
|
| Diclofenac | 1 | 2014 | 11 | 0.120 |
Why?
|
| Mitochondria, Liver | 1 | 2016 | 148 | 0.120 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 145 | 0.120 |
Why?
|
| Kinetics | 1 | 2016 | 1047 | 0.120 |
Why?
|
| Acetaminophen | 1 | 2014 | 111 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 498 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 137 | 0.110 |
Why?
|
| Mice | 2 | 2022 | 8474 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 148 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2014 | 447 | 0.090 |
Why?
|
| Organoids | 1 | 2022 | 42 | 0.050 |
Why?
|
| Cricetinae | 1 | 2022 | 262 | 0.050 |
Why?
|
| Nasal Mucosa | 1 | 2022 | 68 | 0.050 |
Why?
|
| Organelle Biogenesis | 1 | 2020 | 34 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2022 | 562 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 258 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2020 | 305 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 733 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2022 | 400 | 0.040 |
Why?
|
| Lung | 1 | 2022 | 849 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 67 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 68 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1293 | 0.030 |
Why?
|
| Culture Media | 1 | 2014 | 155 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 144 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 314 | 0.030 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2012 | 16 | 0.030 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2012 | 34 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 901 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1745 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 7277 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2012 | 276 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 4655 | 0.020 |
Why?
|
| Aged | 1 | 2014 | 14862 | 0.010 |
Why?
|
| Middle Aged | 1 | 2014 | 21147 | 0.010 |
Why?
|
| Male | 1 | 2014 | 37321 | 0.010 |
Why?
|
| Female | 1 | 2014 | 38074 | 0.010 |
Why?
|